NEMF mutations that impair ribosome-associated quality control are associated with neuromuscular disease

Paige B. Martin et al.

A hallmark of neurodegeneration is defective protein quality control. The E3 ligase Listerin (LTN1/Ltn1) acts in a specialized protein quality control pathway—Ribosome-associated Quality Control (RQC)—by mediating proteolytic targeting of incomplete polypeptides produced by ribosome stalling, and Ltn1 mutation leads to neurodegeneration in mice. Whether neurodegeneration results from defective RQC and whether defective RQC contributes to human disease have remained unknown. Here we show that three independently-generated mouse models with mutations in a different component of the RQC complex, NEMF/Rqc2, develop progressive motor neuron degeneration. Equivalent mutations in yeast Rqc2 selectively interfere with its ability to modify aberrant translation products with C-terminal tails which assist with RQC-mediated protein degradation, suggesting a pathomechanism. Finally, we identify NEMF mutations expected to interfere with function in patients from seven families presenting juvenile neuromuscular disease. These uncover NEMF’s role in translational homeostasis in the nervous system and implicate RQC dysfunction in causing neurodegeneration.
Ribosomes can still undergo translation for a variety of reasons, such as the absence of termination codons followed by translation into the mRNA poly(A) tail (as in nonstop mRNA) or the deficiency of charged tRNAs. Ribosome stalling is a critical problem, as it sequesters ribosomal subunits from the translation-competent pool and, in addition, gives rise to aberrant (incomplete) nascent polypeptide chains that are potentially toxic. In eukaryotes, stalled ribosomes are resolved by rescue factors that split the ribosomal subunits but leave the nascent chain still linked to tRNA, obstructing the exit tunnel in the 60S subunit. This nascent chain-tRNA/60S aberrant structure is recognized by nuclear export mediator factor (NEMF; Rqc2 in yeast). NEMF/Rqc2 facilitates the recruitment of the E3 ligase LTN1 (Ltn1 in yeast), which in turn ubiquitinates the nascent chain, leading to its proteasomal degradation. When ubiquitylation fails, Rqc2 additionally acts by catalyzing the C-terminal elongation of 60S-anchored nascent chains with untemplated Alanine and Threonine tails (CAT tails). An Rqc2 homolog was also found to catalyze C-terminal tailing in bacteria, where the modification acts as a direct proteolysis signal—a function that is likely to have evolved as early as in the Last Universal Common Ancestor. In eukaryotes, the biological functions of CAT tails are not fully understood, however recent evidence suggests that they can assist Ltn1 by exposing Lys residues that may be buried in the ribosomal exit tunnel for ubiquitylation.

We had previously reported that Ltn1 mutation causes motor neuron degeneration in mice. Whether neurodegeneration results from defective RQC and whether defective RQC also contributes to human disease remains unknown. The findings that Ltn1/LTN1 and Rqc2/NEMF work closely in RQC predicted that, if the phenotype of Ltn1 mutant mouse is a consequence of faulty RQC, defective NEMF function might have a similar effect. Accordingly, here we describe two novel mouse models with different N-ethyl N-nitrosourea (ENU)-induced missense mutations in Nemf, as well as a genetically engineered Nemf-deficient model, which exhibit neurodegeneration and motor deficits. Functional analyses show that the ENU-equivalent mutations lead to altered CAT tail synthesis (“CATylation”) by yeast Rqc2. Finally, we describe nine cases from seven unrelated families with neuromuscular phenotypes harboring Nemf variants. Thus, our results provide evidence that Nemf functions in neuronal homeostasis and that its loss causes neurodegeneration and motor phenotypes in mice and humans. These findings, along with the previously described Ltn1 mouse model, strongly point to RQC as a critical protein quality control pathway protecting neurons against degeneration.

Results

Mouse Nemf mutations result in progressive motor phenotypes. Through independent ENU mutagenesis screens, two mouse lines with abnormal gait and muscle wasting were identified as carrying homozygous mutations in Nemf: C57BL/6NemfR86S/R86S (nucleotide: A258T; protein: R86S) and C57BL/6NemfR487G/R487G (nucleotide: A1460G; protein: R487G) (Fig. 1a, b). Henceforth, we refer to these homozygous mutant mice as R86S and R487G, respectively.

R86S mice appear normal at birth but by 2 weeks of age exhibit an overt motor phenotype that manifests as an abnormal waddling-like gait (Supplementary Movie 1), as well as smaller body size (Fig. 1a) with decreased growth rate thereafter (Fig. 1c). In comparison, R487G mice have less marked motor defect and growth reduction (Fig. 1b, c) and only by 10 weeks of age begin to display abnormal gait and hindlimb wasting (Supplementary Movie 2). Disease is progressive in both models. R86S mice die prematurely with a median lifespan of 20 days, with 20% of the animals living past 40 days, whereas R487G mice live past 2 years (Fig. 1d). Both +/+R487G and +/+R86S (heterozygous animals) have survival and growth rates similar to wild-type mice (Supplementary Fig. 1a, b).

Since Nemf mutant mice exhibit abnormal gait, we further examined their motor function. Although the latency to fall in an inverted wire hang assay was comparable for wild-type and R86S mice at 2 weeks of age (Supplementary Fig. 2a), by 8 weeks surviving R86S mice were completely unable to perform the test (Fig. 1e). R487G mice also displayed shorter latency to fall compared to wild-type mice at 8 weeks (prior to overt phenotype onset) but did not exhibit further progression of the defect when examined at 55 weeks of age (Fig. 1e; Supplementary Fig. 2c). Heterozygous +/+R86S and +/+R487G animals appeared unaffected at all observed timepoints (Supplementary Fig. 2a–c).

Nemf R86S and R487G mice exhibit neurogenic atrophy. To determine the cause of impaired motor function in Nemf mutant mice, a histopathological examination of hindlimb muscle was performed. Tissue cross-sections revealed decreased muscle fiber size in the medial gastrocnemius (MG) muscle of 16- to 18-day-old R86S mice compared to wild-type animals (Supplementary Fig. 3a, b). Whereas the MG muscle of R487G mice appeared histologically normal at 2 weeks of age (not shown), by 55 weeks of age localized, nonuniform clusters of atrophied fibers, collagenous fibrosis, and fatty infiltration were observed (Supplementary Fig. 3c).

To investigate the basis of the muscle atrophy, the integrity of neuromuscular junctions (NMJ) was analyzed (Fig. 2a–f), revealing denervation and fragmentation of postsynaptic terminals in 8-week-old R86S mice (Fig. 2a, c, f). At the same timepoint, R487G exhibited more fully and partially occupied junctions than R86S mice (Fig. 2b, f), correlating with the severity of their respective motor phenotypes. Nonetheless, NMJ occupancy was already decreased in R487G compared to wild-type mice at 8 weeks and denervation continued to progress with age (Fig. 2d–f).

Mutant mice exhibit progressive axonal degeneration. The loss of NMJs suggested that muscle atrophy of Nemf mutant mice had a neurogenic origin. To investigate this possibility, we assessed the extent of neuronal degeneration in Nemf mutants through the analysis of myelinated axons in the femoral nerve motor branch. At 2 weeks of age, the number of axons were comparable in wild-type and Nemf mice (Supplementary Fig. 4a) with similar overall morphology and axonal diameter distribution suggesting that our findings do not reflect a developmental defect (Fig. 2g–i, Supplementary Fig. 4b, c). However, by 16–18 days, R86S mice began to exhibit femoral motor myelinated axon loss (Supplementary Fig. 4a, b), which by late end-stage (8 weeks of age) was further reduced (~30%) (Fig. 2j, l, o) with a shift in axon diameter distribution indicative of the largest fibers being most impacted (Supplementary Fig. 4c). R487G mice also displayed a reduction of the largest diameter fibers at 8 weeks of age (Fig. 2k, o, Supplementary Fig. 4c). Although no further age-related degeneration was observed in R487G animals (Fig. 2m–o), an age-dependent shift in axon diameter distribution towards smaller fibers was observed (Supplementary Fig. 4c). Heterozygous mice exhibited no axonal degeneration, even past 2 years of age; thus, both alleles appear to behave in a purely recessive manner (Supplementary Fig. 4d).

In contrast to peripheral neuropathies, characterized by loss of distal axons such as those in the femoral motor nerve branch, motor neuron disease can be evidenced by the loss of neuronal cell bodies and their proximal axons, such as the lumbar ventral root exiting from the spinal cord. To determine if mutations in Nemf cause a purely peripheral neuropathy or also degeneration of spinal motor axons, lumbar ventral roots (at the L4 level) were examined for cell body-proximal axon loss. As with the distal part
of axons, both the R86S and R487G mice exhibited loss of proximal motor axons as early as 16–18 days (Fig. 2p, Supplementary Fig. 5a, b). However, R487G also exhibited further reduction of proximal axons between 8 and 55 weeks of age (Fig. 2p, Supplementary Fig. 5c, d), while distal axons reached terminal degeneration by 8 weeks (Fig. 2o). These results suggest a neuronal dying-back mechanism, wherein the disease originates distally. Consistent with a recessive phenotype, proximal L4 ventral roots also show no difference in heterozygous animals (Supplementary Fig. 5e).

Finally, we note that, although Nemf mutant mice exhibit axonal loss associated with motor phenotypes, the disease is not specific to the motor system as preliminary analyses of femoral mouse tissues (Fig. 3a) indicated that R86S and R487G, heterozygous D106 mice appear unaffected, consistent with a recessive loss-of-function mechanism (Supplementary Fig. 8a). In addition, D106 mice display a respiratory distress phenotype at end-of-life, evident by decreased oxygen saturation (Supplementary Fig. 8j) and phrenic nerve degeneration (Supplementary Fig. 8k–m). Thus, D106 mice exhibited a marked reduction in occupied NMJs in the MG at end-of-life (Supplementary Fig. 8b and data not shown). D106 mice exhibited a marked reduction in occupied NMJs in the MG at end-of-life (Supplementary Fig. 8b and data not shown). D106 mice exhibited a marked reduction in occupied NMJs in the MG at end-of-life (Supplementary Fig. 8b and data not shown).

Mouse ENU mutations perturb CATylation activity of NEMF/Rqc2. The observation that NEMF ENU mutant proteins are hypomorphic and cause an age-dependent neurodegenerative phenotype, whereas the complete loss-of-function of either Ltn1 or Nemf results in earlier and more severe phenotypes.}

NEMF-null mice exhibit an early onset neurologic phenotype. Immunoblot analysis of brain and spinal cord extracts indicated that the NEMF ENU mutations did not markedly affect the steady-state levels of the mutant proteins compared to that of the wild-type (Supplementary Fig. 7). In order to assess whether the mutant proteins retain some function (i.e., whether they are hypomorphic), we analyzed mice harboring a putative NEMF-null allele. This allele, generated in the course of CRISPR genetic modifications, has a single nucleotide insertion causing a frameshift and premature termination (nucleotide: 296_297insT; protein: D100GfsX6; henceforth, D106; Supplementary Fig. 8a). Accordingly, no full-length NEMF protein was detected in D106 mouse tissues (Fig. 3a). D106 exhibited more severe phenotypes than R86S or R487G mice, with an early deviation in growth and pre-wean lethality by postnatal day 11 (Fig. 3b–d). Like R86S and R487G, heterozygous D106 mice appear unaffected, consistent with a recessive loss-of-function mechanism (Supplementary Fig. 8b and data not shown). D106 mice exhibited a marked reduction in occupied NMJs in the MG at end-of-life (Supplementary Fig. 8c–e) along with a reduction in peripheral myelinated axons (Fig. 3e, Supplementary Fig. 8f–i). In addition, D106 mice display a respiratory distress phenotype at end-of-life, evident by decreased oxygen saturation (Supplementary Fig. 8j) and phrenic nerve degeneration (Supplementary Fig. 8k–m). Thus, D106 exhibited earlier and more severe neuromuscular changes than R86S and R487G animals. Together, the above results suggest that, similar to the originally described Ltn1 ENU mutation, the missense Nemf ENU mutations are hypomorphic and cause an age-dependent neurodegenerative phenotype, whereas the complete loss-of-function of either Ltn1 or Nemf results in earlier and more severe phenotypes.
as divergent as yeast and bacteria\textsuperscript{11,13}. The R86S mutation is in the vicinity of the universally conserved, catalytic residues D96 and R97 (Fig. 4a). With regard to the R487G mutation, it maps to the structurally adjacent second coil motif, which is also likely to contribute to C-terminal tailing by assisting with A-site tRNA recruitment\textsuperscript{11}.

Since NEMF homologs are well conserved with regard to sequence, structure and function and robust assays for RQC activity are established in yeast, we utilized this model organism for mechanistic studies. Although mammalian NEMF could not functionally replace Rqc2 in yeast (unpublished observations), the residues affected by the ENU mutations in mice are also conserved in yeast (Fig. 4a, Supplementary Fig. 9) so the equivalent mutations were introduced in Rqc2 (R88S and K534G, respectively; Fig. 4a). The equivalent residue of NEMF’s universally conserved D96 in yeast is D98 (Fig. 4a), which was mutated to Tyr\textsuperscript{16}. Rqc2 R88S, K534G, and D98Y mutant levels were comparable to the wild-type protein (Fig. 4b–f).

To investigate the effect of the ENU mutations in C-terminal tailing by Rqc2, we used Ltn1\textsuperscript{Δ} cells a ribosome stalling reporter became readily modified with CAT tails (as evidenced by the formation of a smeared band immediately above the unmodified reporter band; Fig. 4b, c, lanes 2\textsuperscript{11,16,17}). As also reported, CATylation was
Fig. 2 Nefm ENU mutations cause progressive neuromuscular degeneration. a–e Representative images of neuromuscular junction (NMJ) staining of medial gastrocnemius (MG) muscle from mice of indicated genotypes and ages. Tissues were stained for presynaptic vesicles (anti-SV2, green), neurofilaments (anti-neurofilament 2H3, green), and acetylcholine receptor (α-bungarotoxin, red). Unoccupied (arrow) and partially occupied (arrowhead) junctions are highlighted. Scale bar, 60 μm. Inset scale bar, 30 μm. f Quantification of fully innervated, partially innervated or denervated NMJs based on presynaptic and postsynaptic staining overlap. Eight-week-old WT, R487G and R865 mice (n = 4, 5, and 3 respectively), and 55-week-old WT and R487G mice (n = 4 and 3, respectively) were analyzed. By 8 weeks R487G or R865 mice compared to WT (****p < 0.0001), but were not different from one another (p = 0.4391). Fifty-five weeks of age, R487G vs. WT (****p < 0.0001). Data are presented as mean percent occupancy value ± SD. Statistical analysis was performed by two-way ANOVA followed by Tukey’s multiple comparison, for % fully occupied. g–n Representative cross-sections of femoral nerve motor branches from mice of indicated genotypes and ages. Scale bar, 20 μm. o Total myelinated axon number in cross-section of WT and Nefm mutant mice at 8-week-old wild-type (WT), R487G and R865 mice (n = 9, 7, and 4, respectively), and 55-week-old WT and R487G mice (n = 6 and 4, respectively). Eight weeks (WT vs. R487G ****p < 0.0001, WT vs. R865 ****p < 0.0001 and R487G vs. R865 ***p = 0.0005). Fifty-five weeks (WT vs. R487G ****p < 0.0001. R487G 8 weeks vs. 55 weeks **p = 0.001). p Myelinated axon number in cross-sections of L4 ventral roots of WT and Nefm ENU mice. Analysis of 8-week-old WT, R487G and R865 mice (n = 5, 3, and 4, respectively), and 55-week-old WT and R487G mice (n = 4 each). At 8 weeks of age R487G vs. WT *p = 0.0136, R865 vs. WT ****p < 0.0001, R487G vs. R865 **p = 0.0063, by 55 weeks of age R487G vs. WT ****p < 0.0001, R487G 8 weeks vs. R487G 55 weeks **p = 0.0055. o, p Individual data points and mean ± SD are indicated. Statistical analysis was performed by one-way ANOVA followed by Tukey’s multiple comparison (wild-type, orange squares; R487G, purple circles; R865, green triangles). Source data for f, o, p are provided as a source data file.

Fig. 3 Nefm D106* mice display perinatal neurodegeneration and lethality. a Western blot analysis of brain lysates from 10-day-old wild-type (WT), and Nefm D106* hetero- and homozygous mice using anti-NEMF antibody, and anti-GAPDH antibody as loading control. b Eleven-day-old D106* homozygous mice are smaller than WT littermates. Mutant mice display wasting and are unable to upright themselves at this timepoint. c Body weight of WT (green circle, n = 8 day 1, n = 5 days 7 and 11) and D106* homozygous (purple circle, n = 4 days 1 and 7, n = 7 day 11) mice for WT vs. D106* at each 1, 7, and 11 days of age, respectively (n.s.p > 0.9999, ****p < 0.0001, ****p < 0.0001). Mean ± SD is indicated. Statistical analysis was performed by two-way ANOVA followed by Sidak’s multiple comparison. d D106* mice have shortened lifespan. Kaplan–Meier survival curves of D106* homozygous (purple line, n = 9; median survival: 11 days) and WT (green line, n = 9) mice p = 0.0022. Statistical analysis was performed by Log-rank (Mantel–Cox) test with two-tailed p value reported (e), myelinated axon numbers from whole cross-sections of femoral nerve motor branches in 9- to 11-day-old WT and D106* homozygous mice. For motor (WT: n = 3; Nefm D106*: n = 4, ****p < 0.0001) and sensory (WT: n = 3; Nefm D106*: n = 6, **p = 0.0031). Individual data points and mean ± SD are indicated. Statistical analysis was performed by a two-sided unpaired t test. Source data for c, e are provided as a source data file.
wild-type Rqc2 (lane 3), or the “ENU mutant” Rqc2 proteins (lanes 5 and 6) rescued this rqc2Δ phenotype in an otherwise wild-type background, indicating that the mutant proteins are competent to bind to ribosomes and stabilize Ltn1 binding. Thus the ENU mutations appear to cause a selective defect in C-terminal tailing.

To provide further evidence for the CATylation defect of Rqc2 ENU mutants, we analyzed expected consequences of impaired

**Fig. 4 Nemf ENU mutations selectively affect the CATylation function of Rqc2.**

a Domain diagram and partial alignment of mouse NEMF and homologs—human NEMF, fly Caliban, and yeast Rqc2. Sequences flanking residues affected by the ENU mutations are shown. Domains and motifs depicted: NFACT-N (N), helix-hairpin-helix (H), coiled-coil (cc), middle domain (M), NFACT-R (R), and NFACT-C (C). NEMF Arg86 and Arg487 mutated in Nemf ENU mice (* and red rectangles), and yeast Rqc2 Asp98 and Arg99 residues previously implicated in CAT tail synthesis (green rectangle) are indicated.

b WT, ltn1Δ, or ltn1Δ rqc2Δ cells were transformed with the GFP-R12-RFP (GRR) stalling reporter and plasmids encoding Rqc2-FLAG WT, CATylation-deficient D98Y mutant, or ENU-equivalent mutants (R88S and K534G). Immunoblots: anti-GFP and anti-FLAG to monitor reporter and Rqc2 levels, respectively, and anti-Pgk1 as loading control.

c Strains transformed with Rqc2-FLAG and the GRR stalling reporter, as indicated. Immunoblot anti-GFP monitored reporter modification and aggregation.

d Wild-type (WT) and RQC2-deleted (rqc2Δ) cells were transformed with the GRR stalling reporter, and indicated Rqc2-FLAG constructs and analyzed as in "b". e Kless-K2, -K27, or -K36 reporters (see Supplementary Fig. 8) expressed in rqc2Δ cells together with Rqc2-FLAG WT, the CATylation-deficient Rqc2 aaa mutant (Asp9, Asp98, and Arg99 mutated to Ala), or Rqc2-equivalent ENU mutants as indicated. Anti-HA and anti-FLAG blots monitored reporter and Rqc2 expression, respectively. f As in panel "f". Quantification of reporter levels relative to the Pgk1 internal control from three biological replicates, individual values with means ± SEM. For each blot b–e MW markers in kDa are indicated.
CATylation. For example, CAT tails are known to promote nascent chain aggregation when Ltn1-mediated ubiquitylation fails altogether\textsuperscript{16-18}. Accordingly, in ltn1Δ cells (or in ltn1Δ rqc2Δ cells expressing wild-type Rqc2), CAT tail-mediated aggregation of a ribosome stalling reporter was conspicuous (Fig. 4c). In this assay, both Rqc2 ENU mutants were likewise competent to mediate reporter aggregation in ltn1Δ rqc2Δ cells; however, consistent with these mutants’ decreased ability to make CAT tails, aggregates were formed to a lower extent compared to wild-type Rqc2. Similar observations were made when the formation of endogenous aggregates were monitored by using as a readout, the hsp40 Sis1, which becomes stably incorporated into CAT tail-type Rqc2. Similar observations were made when the formation of tails, aggregates were formed to a lower extent compared to wild-type Rqc2. Therefore, engineered an alternative reporter whose Ltn1-mediated ubiquitylation even in the absence of added CAT tails\textsuperscript{14}. We thus engineered an alternative reporter whose Ltn1-mediated ubiquitylation and degradation would be dependent on CAT tail synthesis, because the reporter lacked Lys residues (K-less) except at two positions buried deep within the ribosomal exit tunnel, located 2 residues N-terminal to the ribosome stalling sequence (Kless-K2; Supplementary Fig. 10b). Consistent with a CAT tail requirement for degradation, Kless-K2 reporter levels (anti-HA) were indeed higher in rqc2Δ cells reconstituted with a CATylation-deficient Rqc2 mutant (Rqc2 aaa\textsuperscript{11}) compared to Rqc2 wild-type (Fig. 4e, f). Notably, Kless-K2 levels were intermediate in cells expressing the Rqc2 ENU mutants consistent with those mutants’ partial CATylation defect. As controls, reporters with Lys residues either closer to the opening of the exit tunnel (Kless-K27) or predicted to be already exposed on the outside (Kless-K36) were also tested. As expected, the levels of these reporters in the presence of Rqc2 ENU mutants were low and comparable to the Rqc2 wild-type and aaa mutant (Fig. 4e, f). We additionally verified that all constructs were targeted for degradation in a Ltn1-dependent manner (Supplementary Fig. 10c). These results substantiate the model that CATylation can function to support Ltn1-mediated ubiquitylation and suggest that the Rqc2 ENU mutations interfere with the degradation of a subset of Ltn1 substrates that rely on CAT tails for ubiquitylation.

**NEMF** variants are associated with juvenile neuromuscular disease. Through collaboration facilitated by GeneMatcher\textsuperscript{19}, nine patients from seven unrelated families with likely pathogenic variants in *NEMF* were identified. Seven patients harbored biallelic variants, an eighth patient harbored an inherited variant and a de novo variant (though the chromosomal phase is undetermined, i.e., whether the variants are in cis or trans) and the ninth patient harbored a single de novo missense variant. These patients display intellectual disability and/or early motor neuron disease phenotypes of varying severities and progression, summarized in Table 1. Detailed clinical findings are available (Supplementary Note 1). An Australian case of consanguineous Syrian parents (AUS1-II:3, Fig. 5a–f) presented with axonal neuropathy and spastic paraplegia at 18 months of age; the individual has severe speech delay. Whole-genome sequencing (WGS) identified a homozygous nonsense variant in *NEMF* (c.2608C > T, p.(Arg870*)). In a Turkish family, (DEU1, Fig. 5a) with two individuals presenting with developmental delay and peripheral neuropathy in childhood, a homozygous nonsense variant in *NEMF* was identified (c.2014A > T, p.(Lys672*)). In a Persian family (IRN1, Fig. 5a), a proband presented with hypotonia, developmental delays and severe speech delay; WGS identified a homozygous frameshift variant in *NEMF* (c.2451delA; p.(Ser817fs*7)). In a Saudi Arabian family (SAU1, Fig. 5a) with two individuals presenting with developmental delays, a homozygous frameshift variant in *NEMF* was identified (c.2871_2875delTGTTAG; p.(Asp959fs*2)). In a Caucasian proband (USA1-II:1, Fig. 5a) presenting with gross developmental delay in the second year of life, two NEMF variants were identified: a maternally inherited nonsense variant (c.2011C > T; p.(Arg671*)) and a de novo variant of the start codon (c.1A > T; p.(Met1*)). Chromosomal phase could not be determined based on clinical NGS sequencing. In another Caucasian proband (USA2-II:1, Fig. 5a), who presented with mild hypotonia and speech delays, biallelic NEMF variants were identified by exome sequencing: two maternally inherited missense variants (c.980G > A;p.Arg327Gln and c.2777C > T; p.(Arg926*)) and a maternally inherited frameshift variant (c.2768delA; p.(Lys923Argfs*7)). A Caucasian proband (USA3-II:2, Fig. 5a) who presented with axonal sensorimotor peripheral neuropathy at 17 years of age harbored a de novo missense variant in *NEMF* (c.1658T > C, p.(Ile553Thr)). The variant is absent from gnomAD and predicted to be damaging by all predictor programs, including MutationTaster, “disease causing”; PolyPhen-2, “probably damaging”; Provean, “deleterious”; SIFT, “deleterious”). The substituted p.(Ile553) is conserved through evolution including in yeast (Supplementary Fig. 9). As a second disease-associated variant

**Table 1 Clinical features of affected individuals.**

| Family | AUS1 | DEU1 | DEU1 | IRN1 | SAU1 | SAU1 | USA1 | USA2 | USA3 |
|--------|------|------|------|------|------|------|------|------|------|
| Individual | II:3 | II:3 | II:6 | II:1 | II:1 | II:2 | II:1 | II:1 | II:2 |
| Age (years) | 7+7 mo | 22 | 16 | 28 | 10 + 6 mo | 7 | 6 + 4 mo | 7 + 10 mo | 24 |
| Sex | M | M | F | M | M | F | F | M | M |
| Age at onset (years) | 1.5 | 2 | 1 | 1 | 2 | 2 | 1.7 | 2 | 17 |
| ID/GDD | + | + | + | + | + | + | + | + | + |
| Speech delay | + | + | + | + | + | + | + | + | + |
| Neuropathy (axonal) | + | + | N/A | N/A | N/A | N/A | N/A | N/A | + |
| Ataxia | + | + | + | + | + | + | + | + | + |
| Distal muscle atrophy | + | + | + | + | + | + | + | + | + |
| Hypotonia | + | + | + | + | + | + | + | + | + |
| Respiratory distress | + | + | + | + | + | + | + | + | + |
| Tremor | + | + | N/A | N/A | N/A | N/A | N/A | N/A | + |
| Abnormal brain imaging | N/A | + | N/A | N/A | N/A | N/A | N/A | + | N/A |
| Kyphosis/Scoliosis | + | + | + | + | + | + | + | + | + |

ID/GDD: Intellectual disability/global developmental delay; −: absent, +: present, N/A: not ascertained/not applicable.
pectus excavatum, scoliosis (residual equinovarus foot posturing despite previous orthopedic surgery (the distribution of wild-type (−) and unique mutant (+) alleles in the pedigrees).

Fig. 5 NEMF variants are associated with neuromuscular disease in humans. a Pedigrees of identified families having affected individuals and NEMF variants. ‘−’ indicates wild-type allele, ‘+’ indicates variant allele, arrowhead indicates proband. Different font colors are used to facilitate visualization of the distribution of wild-type (−) and unique mutant (+) alleles in the pedigrees. b–f Clinical photography of 7-year-old subject AUS1-II:3. Asymmetric pectus excavatum, scoliosis (b), and characteristic adducted thumb posture are evident (c). Right foot showing surgical scars with residual equinovarus foot deformity and toe clawing (d). Images showing pectus excavatum, kyphoscoliosis, hip, and knee flexor contractures with distal muscle wasting and residual equinovarus foot posturing despite previous orthopedic surgery (e, f).

Our results indicate that patients with NEMF variants can additionally manifest intellectual disability, most notably speech delay. This conclusion is supported by a genome-wide association analysis which included NEMF variants among several genes potentially implicated in cognitive phenotypes. Similarly, mutation of GTPBP2, a GTPase that mediates the splitting of stalled ribosomes upstream of RQC, causes Jaberi–Elahi syndrome, an early onset neurodegenerative disease characterized by dystonia, motor and sensory neuropathy, ataxia, and cognitive dysfunction. Future experiments will address the potential for cognitive dysfunction in Nemf mutant mice, although we anticipate that the interpretation of such analyses may be confounded by the presence of motor and sensory deficits.

Discussion

Our studies identify Nemf as a novel gene implicated in neurodegeneration and neuromuscular disease in mice and humans. Moreover, this finding, along with the previously described Ltn1 mouse model, strongly point to RQC as a critical molecular pathway protecting neurons against degeneration. This suggests that the presence of variants in NEMF and other RQC factors (e.g., Listerin) should be examined in patients with related diseases.

Our results indicate that patients with NEMF variants can additionally manifest intellectual disability, most notably speech delay. This conclusion is supported by a genome-wide association analysis which included NEMF variants among several genes potentially implicated in cognitive phenotypes. Similarly, mutation of GTPBP2, a GTPase that mediates the splitting of stalled ribosomes upstream of RQC, causes Jaberi–Elahi syndrome, an early onset neurodegenerative disease characterized by dystonia, motor and sensory neuropathy, ataxia, and cognitive dysfunction. Future experiments will address the potential for cognitive dysfunction in Nemf mutant mice, although we anticipate that the interpretation of such analyses may be confounded by the presence of motor and sensory deficits.

The observation that one patient (USA3-II:2) with a heterozygous variant and later onset peripheral neuropathy phenotype may suggest potential dominant-negative impacts from variants in NEMF. Future work will address potential modifiers and determine if this allele could dominantly cause disease in mouse models. Thus far, no motor or sensory peripheral degeneration has been observed in our heterozygous mouse models at one and a half years of age.

The observations that Rqc2 homologs from bacteria to humans have high overall sequence and structural similarity and that residues specifically implicated in the C-terminal tailing modification are strictly conserved (Fig. 4a, Supplementary Fig. 9; refs. 2,11,13) strongly suggests that Rqc2 homologs across all domains of life share a fundamental role in mediating C-terminal tailing in RQC. In fact, this biochemical activity has been reported for a homolog as evolutionarily distant as B. subtilis RqcH11,13. Despite great progress made toward understanding this and other fundamental mechanisms in RQC, new mammalian models have been lacking to establish the physiological relevance of the findings and to directly test predictions regarding molecular mechanisms of neurodegeneration. Our results now show that the neurodegeneration-causing mouse NEMF R86S and R487G mutations selectively interfered with yeast Rqc2’s ability to mediate CAT tail synthesis, and that phenotypic severity is correlated with the extent of their reduction in CATylation activity, thus suggesting both a link between neurodegeneration and defective C-terminal tailing as well as a physiological role for this RQC mechanism in mammals.

Methods

ENU Mutagenesis and mapping. The B6-Nemf R86S line was originally derived from an N-ethyl-N-nitrosourea mutagenesis screen for reproductive defects initiated at The Jackson Laboratory. Chemical mutagenesis was induced in a C57BL/6 background and mutagenized mice were subsequently outcrossed to C3H/HeJ mice. The line was then backcrossed to C57BL/6 for at least 10 generations to obtain the B6-Nemf R86S line (JAX Stock #19392) used in this study. The mutation was mapped to a 4.6 Mb interval in an F2 intercross (Chr. 12: 65846719–70085250 bp, GRCm38) and the only exonic variant detected among 15 candidate genes analyzed was in the Nemf gene. The B6-Nemf R487G line (JAX Stock #18870) was derived from an independent ENU mutagenesis screen for eye phenotypes in a
glutaraldehyde and 2% paraformaldehyde in 0.1 M cacodylate buffer. Nerves were embedded, sectioned, mounted, and stained with hematoxylin and eosin for light microscopic analysis according to standard histological procedures. Samples were imaged on a Leica RM2265 rotary microtome with a diamond knife, with at least 1 µm were cut on a Leica RM2265 rotary microtome with a diamond knife, and 4 °C, and incubated with primary antibodies (1:500 mouse monoclonal IgG1 anti-GAPDH (14C10, Cell Signaling, 1:20,000) antibodies. Immunoblots were developed using anti-rabbit IgG (1:5000, Santa Cruz) antibodies. The MG muscle was dissected and snap-frozen in liquid nitrogen and lysed with glass beads under denaturing conditions. Protein quantitation was performed by the BCA method. TOTALLY, 7.5–30 µg of protein extract were reusseated in sample buffer (1% sodium dodecyl sulfate, 0.05% bromophenol blue, 5% glycerol, 50 mM dithiothreitol, 50 mM Tris-Cl (pH 6.8)) and incubated at 100 °C for 5 min. Protein samples were run on Novex or NuPage gels (Invitrogen), transferred onto polyvinylidene fluoride (PVDF) membrane and immunoblotted for anti-FLAG tag (M2, Sigma, 1:1000), anti-HA (3E10, Roche. 1:1000), anti-GFP (Roche clone 7.1 M2, Sigma, 1:1000) antibodies. Image analysis was performed with ImageJ (v1.52p) stitching grid/pairwise plugin.

Histological analysis of gastrocnemius muscle. Mice were euthanized and right hindlimb was extracted and post-fixed in Bouin’s fixative. Whole hindlimbs were cross-sectioned through the middle portion of lower and upper leg. The sectioned tissues were then paraffin-embedded, sectioned, mounted, and stained with hematoxylin and eosin for light microscopic analysis according to standard histological procedures. Sections were stained using a Nikon Eclipse E600 microscope with a 40× and 100× objectives. The total number of myelinated axons in each nerve was counted using an automated threshold method in ImageJ (v1.52p) with manual confirmation.

Oxygen saturation measurements. The MouseOx™ Pulse-oximeter (Starr Life Sciences, Oakmont PA) was used to measure SpO2 on 10- and 11-day-old D106° mice and unaffected littersates. It was determined that there were no sex differences in phenotype and therefore the data was presented as mixed sex. For oxygen saturation measurements, and denervation as when positive for ACHR but negative for pre-synaptic nerve staining. It was determined that there were no sex differences in phenotype and therefore the data was presented as mixed sex, with similar numbers of males and females. Mice were measured in a darkened room and held until calm, before placing the extra-small collar probe on the neck with the reader window near the carotid artery. Readings were taken for approximately 2–10 min from each mouse. Readings were sorted by Excel spreadsheet and R, for readings that had no SpO2 error codes in a block.

S. cerevisiae strains and constructs. Strains used in this work are isogenic to BY4741. The GFP-Ang2-RFP (referred to as GRR) construct was a gift of J. Weissman (UCSF). To generate Rqc2 constructs, the coding sequence of Saccharomyces cerevisiae Rqc2 was amplified by PCR with the 3x FLAG epitope added at the C-terminus, and cloned into the Ycplac111 vector (LEU2 marker, CEN, and GPD promoter). Point mutations were inserted by site directed mutagenesis via gene synthesis. To generate the Rqc2 Δa mutation, a fragment was synthesized to contain the first 181 amino acids of Rqc2 with D9A, D9A and R99A mutations flanked with 5’ Psfl and 3’ SpeI restriction sites (IDT). The gene fragment was cloned into the Rqc2-3X FLAG construct by digestion with Psfl and Pstl followed by triple ligation. The kess-K2, -K27, and -K36 replacements were generated by inserting PCR of the HA-klac expression construct to introduce additional Lys-Ala-Gly-Lys (AAAAGGTGCATAAA) sequences in amino acid positions 2, 27, and 26 N-terminal of the R12 stalling signal.

Protein expression analyses. Yeast total soluble extracts were prepared from cells that were flash frozen in liquid nitrogen and lysed with glass beads under denaturing conditions. Protein quantitation was performed by the BCA method. TOTALLY, 7.5–30 µg of protein extract were reusseated in sample buffer (1% sodium dodecyl sulfate, 0.05% bromophenol blue, 5% glycerol, 50 mM dithiothreitol, 50 mM Tris-Cl (pH 6.8)) and incubated at 100 °C for 5 min. Protein samples were run on Novex or NuPage gels (Invitrogen), transferred onto polyvinylidene fluoride (PVDF) membrane and immunoblotted for anti-FLAG tag (M2, Sigma, 1:1000), anti-HA (3E10, Roche. 1:1000), anti-GFP (Roche clone 7.1 M2, Sigma, 1:1000), anti-Pgk1 (Invitrogen clone 2C2DS8, 1:10,000) and anti-Suc1 (E. Craig, 1:1,000, 20,000-20,000). Blots corresponding to yeast work (Fig. 4b–e, Supplementary Fig. 10a, c) are available uncropped in Supplementary Figs. 11 and 12. For mouse experiments, spinal cord and brain were collected immediately following cervical dislocation, snap-frozen in liquid nitrogen and stored at ~80 °C. Tissues were homogenized in lysis buffer (20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 5 mM EDTA (pH 8)), protease inhibitor (Complete Protease Inhibitor Cocktail, Roche) on TissueLyserII (Qiagen), incubated in 0.5% NP-40 for 30 min at 4 °C and then precleared at 12 °C for 1 h. Protein concentration was determined by BCA method. Protein samples were boiled in sample buffer and were run on ExpressPAGE gels (Gene Script), transferred onto PVDF membrane and immunoblotted with anti-NEM (Proteintech, 11840-1AP, 1:1000) and anti-GAPDH (14C16, Cell Signaling,1:20,000) antibodies. Immunoblots were developed using ECL reagent (Thermo Fisher, GE healthcare) and imaged in LAS 4000 Imagor or on X-ray film. Uncropped blots from Fig. 3a and Supplementary Fig. 7 are available in Supplementary Figs. 11 and 12.
Sequence alignment. Amino acid sequences were aligned using CLUSTAL W (V2.1)35 and files were generated by Strap software (September 2012 version)35. Sequence similarity was calculated using the Sequence Manipulation Suite(V2.0)34. Alignment plot was generated by PHALIGN(V2.0)35.

Ethics approval. The participants in this study were identified through the GeneMatcher database19 where clinicians and researchers with variants in genes can identify groups with similar genotype/phenotype findings and collaborate. Informed consent was obtained from all individuals included in the study. Approval for the studies has been from the following: The Institutional Review Board (IRB) at Baylor College of Medicine (protocol number H-29697); considered IRB exempt at the University of South Florida and Mission Fullerton Genetics Center; The Australian Genomics Neuromuscular Disorders ethics committee approval from Melbourne Health (HRREC/16/MH221); approval from the ethics commission of Otto-von-Guericke-Universität and the Medizinischen Fakultät at Universität Magdeburg AöR; the IRB at The University college London; the IRB at King Fahad Medical City (IRB#19-512). The authors affirm that human research participants provided informed consent for the publication of the images in Fig. 5b.

Patient DNA sequencing. USA1 and USA2. Exons and flanking splice junctions were captured from genomic DNA using the IDT xGen Exome Research Panel v1.0. Massively parallel sequencing (NextGen) was performed on an Illumina system with 100 bp or greater paired-end reads. Reads were aligned to human genome build GRCh37/UCSC hg19, and analyzed for sequence variants using a custom-developed analysis tool. Whole-exome sequencing (WES) data for all sequenced family members was analyzed using the GeneDx XomeAnalyzer. This includes nucleotide and amino acid annotations, population frequencies (NHBLI Exome Variant Server, 1000 Genomes, and internal databases), in silico prediction tools, amino acid conservation scores, and mutation references. The identified variants were filtered based on inheritance patterns, variant type, gene lists of interest developed internally, phenotype, and population frequencies, as appropriate36. The general annotation criteria for variant classification are publicly available on the GeneDx ClinVar submission page37.

USA3 clinical exome sequencing was carried out at Baylor Genetics Laboratories as part of the clinical work up and his parents’ DNAs were sequenced at the Human Genome Sequencing Center at Baylor College of Medicine as part of the Baylor-Hopkins Center for Mendelian Genomics (BHCMG) research initiative. Briefly, genomic DNA underwent exome capture with Baylor College of Medicine Human Genome Sequencing Center core design (52 Mb, Roche NimbleGen, RRID: nif-0000-31466), and were sequenced on the HiSeq platform (Illumina) with Human Genome Sequencing Center core design (52 Mb, Roche NimbleGen, RRID: nif-0000-31466), and were sequenced on the HiSeq platform (Illumina) with ∼100× depth of coverage. Using the Mercury in-house bioinformatics pipeline, sequence data was aligned and mapped to the human genome reference sequence (hg19)38.

AUS1. Whole genome sequencing (Illumina HiSeq) of the proband was performed at Kinghorn Center for Clinical Genetics, Garvan Institute of Medical Research. Data were analyzed using the Seave bioinformatic analysis pipeline39.

DEU1. WES was performed with leukocyte genomic DNA from both affected children using the capture library SureSelectX Human All Exon v5 + UTRs (Agilent Technologies) for enrichment and sequencing on a Illumina HiSeq2500 instrument (2 × 100 bp, paired end run). The mean coverage of the target sequence was 50×. The obtained sequence data was analyzed using the Varvis genome platform v1.12.0 (Limbus Medical Technologies GmbH). IRN1: WES of proband’s DNA was performed. Exomes were enriched with HiSeq 3000 to an average sequence depth of 91×. Variants were called and annotated with ANNOVAR40. In accordance with the recessive mode of inheritance, priority was given to rare biallelic functional variants with allele frequency <0.001% in public databases, including 1000 Genomes project, NHBLI Exome Variant Server, Iranian, GMAC Varamine and gnomAD as well as our in-house database consisting of 14,000 exomes. No plausible compound heterozygous or homozygous variants were identified in genes previously associated with neurological phenotypes.

SAU1. Clinical Exome Sequencing (BGI Europe) was carried out using an Illumina HiSeq 4000 to an average depth of coverage of 150× with automated adapter trimming of the fastq sequences. DNA sequence quality metrics were carried out using FASTQC version: 0.11.7. Alignment, quality filtering and variant identification was undertaken using commercially available algorithms. Human reference assemblies were aligned against GRCh37.p13. QIAGEN Clinical Insight—Interpret software was used in sequence analysis and interpretation. Confirmation Sanger test was performed for the index case as well as parent and two siblings.

Statistics and reproducibility. Statistical tests were performed using GraphPad’s Prism (v7) software. A threshold of p < 0.05 was considered significant. Normality of distribution was determined using the Shapiro-Wilk test. For normality test we used MATCH2015SM’s Prism (v7). For assays with data displayed with combined sex, it was determined that there were no sex-dependent differences in phenotype and similar numbers of males and females were used. Outliers were not removed from phenotypic data. Significance was determined using the test indicated in the figure legends. Results are presented as means ± SD, with individual data points where n < 10.

For reproducibility, NMJs and axon counts were analyzed genotype blind. For the representative panels Fig. 2a–e are associated with the data collected in Fig. 2f. Representative images in Fig. 2g–n are associated with the data collected in Fig. 2o. Representative image panel Supplementary Fig. 4b is associated with data collected in Supplementary Fig. 4a. Representative image panels Supplementary Fig. 5b–d are associated with the data collected in Fig. 2p and Supplementary Fig. 5a. The representative image panel Supplementary Fig. 4k–l is associated with data collected in Supplementary Fig. 4j. The representative image panels Supplementary Fig. 8e–f are associated with data collected in Fig. 3e. The representative image panels in Supplementary Fig. 8l, m are associated with data collected in Supplementary Fig. 8k. Supplementary Fig. 3a, b are representative of n = 4 WT and n = 4 R487S and Supplementary Fig. 3c is representative of n = 8 WT and n = 4 R487G biological replicates for yeast assays (Fig. 4 and Supplementary Fig. 10), once assay conditions were defined, experiments were independently replicated successfully at least 3 times and representative data are shown. For mouse protein assays (Fig. 3a, Supplementary Fig. 7a, b), protein lysates of at least four mice for each strain and genotype and multiple organs were tested to confirm lack of NEMF expression. All attempts were successful.

Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability. The data that support the findings of this study are available as source data in the data source file. Variant information will be available upon reasonable request and have been submitted to ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/?term=NEMF%5Bgene%5D30, AnVil (https://anvilproject.org/) and the European Genome-phenome Archive (https://www.ebi.ac.uk/ega/home) for public access. Data for genetic matches with NEMF variants can be found on GeneMatcher19 available to clinicians and researchers describing patients with variants of interest. The variant summary statistics work makes use of the following publicly available databases: ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/?term=NEMF%5Bgene%5D30, Genome Assembly database (Gnomad.V2.1.1, GRCh37.p13, Gnomad2019), greater Middle East (GME) Varamine (V1) (http://igm.ucsd.edu/gme/32, Iranome (http://www.iranneo.me/33, and 1000 Genomes Project (https://www.internationalgenome.org/1000-genomes-browsers)34. Source data are provided with this paper.

Received: 24 January 2020; Accepted: 11 August 2020; Published online: 15 September 2020

References
1. Defenuillère, Q. & Fromont-Racine, M. The ribosome-bound quality control complex: from aberrant peptide clearance to proteostasis maintenance. Curr. Genet. 63, 997–1005 (2017).
2. Joazeiro, C. A. P. Mechanisms and functions of ribosome-associated protein quality control. Nat. Rev. Mol. Cell Biol. 20, 368–383 (2019).
3. Pisareva, V. P., Skabkin, M. A., Hellen, C. U. T., Pestova, T. V. & Pisarev, A. V. Disassociation by Pelota, Hbs1 and ARCE1 of mammalian vacant 80S ribosomes and stalled elongation complexes. EMBO J. 30, 1804–1811 (2011).
4. Shao, S., von der Malsburg, K. & Hegg, R. S. Listerin-dependent nascent protein ubiquitination relies on ribosome subunit dissociation. Mol. Cell 50, 637–648 (2013).
5. Shoemaker, C. J., Eyle, D. E. & Green, R. Dom34-Hbs1 promotes subunit dissociation and peptide-tRNA drop-off to initiate no-go decay. Science 330, 369–372 (2010).
6. Bengtson, M. H. & Joazeiro, C. A. P. Role of a ribosome-associated E3 ubiquitin ligase in protein quality control. Nature 467, 470–473 (2010).
7. Brandman, O. et al. A ribosome-bound quality control complex triggers degradation of nascent peptides and signals translation stress. Cell 151, 1042–1054 (2012).
8. Defenuillère, Q. et al. Cdcl48-associated complex bound to 60S particles is required for the clearance of aberrant translation products. Proc. Natl Acad. Sci. USA 110, 5046–5051 (2013).
9. Lyumkis, D. et al. Structural basis for translational surveillance by the large ribosomal subunit-associated protein quality control complex. Proc. Natl Acad. Sci. USA 111, 15981–15986 (2014).
10. Shao, S., Brown, A., Santhanam, B. & Hegg, R. S. Structure and assembly pathway of the ribosome quality control complex. Mol. Cell 57, 433–444 (2015).
11. Shen, P. S. et al. Rqc2p and 60 S ribosomal subunits mediate mRNA-independent elongation of nascent chains. Science 347, 75–78 (2015).
12. Verma, R., Oania, R. S., Kolawa, N. J. & Deshaies, R. J. Cdc48/p97 promotes degradation of aberrant nascent polypeptides bound to the ribosome. Elife 2, 1–17 (2013).
13. Lytvynenko, I. et al. Alanine tails signal proteolysis in bacterial ribosome-associated quality control. Cell 178, 76–90.e22 (2019).
14. Kostova, K. K. et al. CAT-tailing as a fail-safe mechanism for efficient degradation of stalled nascent polypeptides. Science 357, 414–417 (2017).
15. Chu, J. et al. A mouse forward genetics screen identifies LISTERIN as an E3 ubiquitin ligase involved in neurodegeneration. Proc. Natl Acad. Sci. USA 106, 2097–2103 (2009).
16. Yonashiro, R. et al. The Rqc2p/Tae2 subunit of the ribosome-associated quality control (RQC) complex marks ribosome-stalled nascent polypeptide chains for aggregation. Elife 5, 1–16 (2016).
17. Choe, Y.-J. et al. Failure of RQC machinery causes protein aggregation and proteotoxic stress. Nature 531, 191–195 (2016).
18. Defenouillé, Q. et al. Rqc1 and In1 prevent c-terminal alanine-throneine tail (cat-tail)-induced protein aggregation by efficient recruitment of cd48 on stalled 60s subunits. J. Biol. Chem. 291, 12245–12253 (2016).
19. Sobreira, N., Schiettecatte, F., Valle, D. & Hamosh, A. GeneMatcher: a matching tool for connecting investigators with an interest in the same gene. Hum. Mutat. 36, 928–930 (2015).
20. Richards, S. et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 17, 405–424 (2015).
21. Anazi, S. et al. Clinical genetics expands the morbid genome of intellectual disability and offers a high diagnostic yield. Mol. Psychiatry 22, 615–624 (2017).
22. Ischikawa, R. et al. Ribosome stalling induced by mutation of a CNS-specific tRNA causes neurodegeneration. Science 345, 455–459 (2014).
23. Bertoli-Avella, A. M. et al. Biallelic inactivating variants in the GTPBP2 gene cause a neurodevelopmental disorder with severe intellectual disability. Eur. J. Hum. Genet. 26, 592–598 (2018).
24. Carter, M. T. et al. Clinical delineation of GTPBP2-associated neuro-ectodermal syndrome: Report of two new families and review of the literature. Clin. Genet. 95, 601–606 (2019).
25. Jaberi, E. et al. Identification of mutation in GTPBP2 in patients of a family with neurodegeneration accompanied by iron deposition in the brain. Neurobiol. Aging 38, 216.e11–216.e18 (2015).
26. Handel, M. A., Lessard, C., Reinholdt, L., Schimenti, J. & Eppig, J. J. Mutagenesis as an unbiased approach to identify novel contraceptive targets. Mol. Cell. Endocrinol. 250, 201–206 (2005).
27. Maddox, D. M. et al. An ENU-induced mutation in the Mertk gene (Mertk nm12) leads to a slow form of retinal degeneration. Investig. Ophthalmol. Vis. Sci. 52, 4703–4709 (2011).
28. Bogdank, L. P. & Loss D. of the E3 ubiquitin ligase LRSAM1 sensitizes peripheral axons to degeneration in a mouse model of Charcot-Marie-Tooth disease. Dis. Model. Mech. 6, 780–792 (2013).
29. Pribisich, S., Saalfeld, S. & Tomancak, P. Globally optimal stitching of tiled 3D fluorescent images. Nat. Methods 4, 781–787 (2007).
30. Yan, W. & Craig, E. A. The glycine-phenylalanine-rich region determines the specificity of the yeast Hsp40 Sis1. Mol. Cell. Biol. 19, 7751–7758 (1999).
31. Larkin, M. A. et al. Clustal W and Clustal X version 2.0. Bioinformatics 23, 2947–2948 (2007).
32. Yeh, C., Gah, M., Weyland, B., Wieland, T. & Gille, A. Alignment-Annotator web server: rendering and annotating sequence alignments. Nucleic Acids Res. 42, 3–6 (2014).
33. Stothard, P. The Sequence Manipulation Suite: javascript programs for analysing and formatting protein and DNA sequences. Biotechniques 28, 1102–1104 (2000).
34. Aarsland, A., Swe, K. W., Bolanos, A., Olofsson, P. & Mortensen, P. Flexible sequence similarity searching with the FASTA3 program package. Methods Mol. Biol. 132, 185–219 (2000).
35. Rutter, K. et al. Clinical application of whole-exome sequencing across clinical indications. Genet. Med. 18, 696–704 (2016).
36. Landrum, M. J. et al. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 46, D1062–D1067 (2018).
37. Pehlivan, D. et al. The genomics of arthrogryposis, a complex trait: candidate genes and further evidence for oligogenic inheritance. Am. J. Hum. Genet. 105, 132–150 (2019).
38. Gayevskiy, V., Roscili, T., Dinger, M. E. & Cowley, M. J. Seave: a comprehensive web platform for storing and interrogating human genomic variation. Bioinformatics 35, 122–125 (2019).
Paige B. Martin1,2,26, Yu Kigoshi-Tansho3,26, Roger B. Sher4,5, Gianina Ravenscroft6, Jennifer E. Stauffer1, Rajesh Kumar3, Ryo Yonashiro7, Tina Müller7, Christopher Griffith8, William Allen9, Davut Pehlivan10,11, Tamar Harel12, Martin Zenker13, Denise Howting6, Denny Schanze13, Eissa A. Faqeih14, Naif A. M. Almontashiri15,16, Reza Maroofian17,18, Henry Houlden17,18, Neda Mazaheri19, Hamid Galehdari19, Ganka Douglas20, Jennifer E. Posey10, Monique Ryan21,22, James R. Lupski10,11,23,24, Nigel G. Laing6, Claudio A. P. Joazeiro3,25,27, & Gregory A. Cox1,27

1The Jackson Laboratory, Bar Harbor, ME, USA. 2The University of Maine, Graduate School of Biomedical Science and Engineering, Orono, ME, USA. 3Center for Molecular Biology of Heidelberg University (ZMBH), DKFZ-ZMBH Alliance, Heidelberg, Germany. 4Department of Neurobiology & Behavior, Stony Brook University, Stony Brook, NY, USA. 5Center for Nervous System Disorders, Stony Brook University, Stony Brook, NY, USA. 6Harry Perkins Institute of Medical Research, Centre for Medical Research, University of Western Australia, Nedlands, WA, Australia. 7Department of Molecular Medicine, Scripps Research, Jupiter, FL, USA. 8College of Medicine Pediatrics, University of South Florida, Tampa, FL, USA. 9Mission Fullerton Genetics Center, Mission Health, Ashevile, NC, USA. 10Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA. 11Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX, USA. 12Department of Genetic and Metabolic Diseases, Hadassah-Hebrew University Medical Center, Jerusalem, Israel. 13Institute of Human Genetics, Otto-von-Guericke University Magdeburg, Magdeburg, Germany. 14Department of Genetics, King Fahad Medical City, Riyadh, Saudi Arabia. 15The Center for Genetics and Inherited Diseases, Taibah University, Almadinah Almunwarah, Saudi Arabia. 16Faculty of Applied Medical Sciences, Taibah University, Almadinah Almunwarah, Saudi Arabia. 17Neurogenetics Laboratory, UCL Queen Square Institute of Neurology, London, UK. 18The National Hospital for Neurology and Neurosurgery, London, UK. 19Department of Genetics, Faculty of Science, Shahid Chamran University of Ahvaz, Ahvaz, Iran. 20GeneDx, Inc, Gaithsberg, MD, USA. 21Department of Neurology, The Royal Children’s Hospital, Melbourne, VIC, Australia. 22Murdoch Children’s Research Institute and University of Melbourne, Melbourne, VIC, Australia. 23Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA. 24Texas Children’s Hospital, Houston, TX, USA. 25Department of Molecular Medicine, Scripps Research, La Jolla, CA, USA. 26These authors contributed equally: Paige B. Martin, Yu Kigoshi-Tansho. 27These authors jointly supervised this work: Claudio A. P. Joazeiro, Gregory A. Cox.

✉email: c.joazeiro@zmbh.uni-heidelberg.de; Greg.Cox@jax.org